Salmefamol

A detailed overview of the drug Salmefamol, its uses, mechanism, and related information.

Salmefamol is a beta-2 adrenergic receptor agonist primarily used as a bronchodilator in the treatment of asthma and other conditions involving reversible airway obstruction. It is part of the sympathomimetic class of drugs, which mimic the effects of endogenous catecholamines like epinephrine and norepinephrine.

Pharmacology

Salmefamol works by selectively stimulating beta-2 adrenergic receptors in the smooth muscle of the airways, leading to muscle relaxation and bronchodilation. This action helps to alleviate symptoms such as wheezing, coughing, and shortness of breath in patients with obstructive airway diseases.

Mechanism of Action

Upon inhalation, Salmefamol binds to beta-2 adrenergic receptors on the surface of bronchial smooth muscle cells. This binding activates adenylate cyclase, increasing the intracellular concentration of cyclic adenosine monophosphate (cAMP). Elevated cAMP levels lead to the activation of protein kinase A (PKA), which phosphorylates target proteins that result in muscle relaxation and bronchodilation.

Pharmacokinetics

Salmefamol is typically administered via inhalation, allowing for rapid onset of action. The drug is metabolized primarily in the liver and excreted in the urine. The half-life of Salmefamol is approximately 4-6 hours, making it suitable for use in both acute and maintenance therapy.

Clinical Uses

Salmefamol is indicated for the relief of bronchospasm in conditions such as:

• Asthma
• Chronic obstructive pulmonary disease (COPD)
• Exercise-induced bronchoconstriction

Side Effects

Common side effects of Salmefamol include:

• Tremor
• Tachycardia
• Palpitations
• Headache
• Nervousness

Serious side effects, though rare, may include:

• Paradoxical bronchospasm
• Hypokalemia
• Hyperglycemia

Contraindications

Salmefamol should not be used in patients with known hypersensitivity to the drug or any of its components. Caution is advised in patients with cardiovascular disorders, hyperthyroidism, or diabetes mellitus.

Interactions

Salmefamol may interact with other medications, including:

• Beta-blockers, which may reduce its effectiveness
• Diuretics, which may increase the risk of hypokalemia
• Monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants, which may potentiate cardiovascular effects

Also see

• Beta-2 adrenergic receptor
• Bronchodilator
• Asthma management
• Chronic obstructive pulmonary disease

Salmefamol
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	15302-04-0
PubChem	3033981
DrugBank	DB01285
ChemSpider	2298495
KEGG	D08595

• 

  Salmefamol